Trends in hepatitis C virus infection among patients in the HIV outpatient study, 1996-2007

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 3, 2010, Pages 388-396

  Spradling, Philip R ^a   Richardson, James T ^b   Buchacz, Kate ^a   Moorman, Anne C ^a   Finelli, Lyn ^a   Bell, Beth P ^a   Brooks, John T ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CERNER CORPORATION   (United States)

Author keywords

Coinfection; HCV; HIV; Prevalence; Testing

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; ETHNICITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSURANCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORBIDITY; MORTALITY; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RACE; SCREENING; SEXUAL TRANSMISSION; STATISTICAL ANALYSIS;

ADULT; AMBULATORY CARE; COMORBIDITY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 77649211285     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b67527     Document Type: Article

References (52)

1. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus. Clin Infect Dis. 2001;32:492-497.
2. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240-247.
3. Louie JK, Ling CH, Osmond DH, et al. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis. 2002; 186:1023-1027.
4. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803-1809.
5. Fleishman JA, Hellinger FH. Recent trends in HIV-related inpatient admissions 1996-2000: a 7-state study. J Acquir Immune Defic Syndr. 2003;34:102-110.
6. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy; emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121-130.
7. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005;40:609-616.
8. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799-805.
9. Smith D, Gardner L, Phelps R, et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health. 2005;80:676-688.
10. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194-200.
11. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;36:363-367.
12. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-781.
13. Deuffic-Burban S, Poynard T, Sulkowski MS, et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007; 14:107-115.
14. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
15. Wong J, McQuillan GM, McHutchinson JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569.
16. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36:S30-S34.
17. Murrill CD, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002;92:385-387.
18. Huemer HP, Prodinger WM, Larcher C, et al. Correlation of hepatitis C virus antibodies with HIV-1 seropositivity in intravenous drug addicts. Infection. 1990;18:122-123.
19. Malone JD, Hyams KC, Smith ES, et al. Hepatitis C infection in an HIV-1 positive military population. J Acquir Immune Defic Syndr. 1992;5: 427-428.
20. Brau N, Bini EJ, Shahidi A, et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol. 2002;97:2071-2078.
21. Goulet JL, Fultz SL, McGinnis KA, et al. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-coinfected veterans. AIDS. 2005;19(Suppl 3):S99-S105.
22. Laurian Y, Blanc A, Delaney SR, et al. All exposed hemophiliacs have markers of HCV. Vox Sang. 1992;62:55-56.
23. Weiss ES, Cornwell EE III, Wang T, et al. Human immunodeficiency virus and hepatitis testing and prevalence among surgical patients in an urban university hospital. Am J Surg. 2007;193:55-60.
24. Francois M, Dubois F, Brand D, et al. Prevalence and significance of hepatitis C virus (HCV) viremia in HCV antibody-positive subjects from various populations. J Clin Microbiol. 1993;31:1189-1193.
25. Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus coinfection in vulnerable populations. AIDS. 2005;19(Suppl 3): S13-S19.
26. Santiago-Munoz P, Roberts S, Sheffield J, et al. Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2005;193(pt 2):1270-1273.
27. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients coinfected with human immunodeficiency virus: a cross-sectional analysis of the U.S. Adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.
28. Tedaldi EM, Hullsiek KH, Malvestutto CD, et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis. 2003;36: 1313-1317.
29. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
30. Moorman AC, Holmberg SD, Marlowe SI, et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV Outpatient Study (HOPS). Ann Epidemiol. 1999;9:349-357
31. CDC; USPHS/IDSA Prevention of Opportunistic Infections Working Group. Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1999 48(RR10) 1-59.
32. Van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of international HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 2009;136: 1609-1617.
33. Van der Laar TJW, Van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 2007;196:230-238.
34. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV Atlanta VA Cohort Study. Clin Infect Dis. 1999;29:150-154.
35. Hagan H. Hepatitis C transmission dynamics in injecting drug users. Subst Use Misuse. 1998;33:1197-1212.
36. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C infection among injection drug users. Medicine. 1995;74:212-220.
37. Villano SA, Vlahov D, Nelson KE, et al. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997;35:3274-3277.
38. Hayashi PH, Flynn NH, McCurdy SA, et al. Prevalence of hepatitis C antibodies among patients infected with human immunodeficiency virus. J Med Virol. 1991;33:177-180.
39. Quan CM, Krajden M, Grigoriew GA, et al. Hepatitis C infection in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1993;17:117-119.
40. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2005. Clin Infect Dis. 2008;46:1852-1858.
41. Armstrong GL. Injection drug users in the United States, 1979-2002: an aging population. Arch Intern Med. 2007;167:166-173.
42. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562
43. CDC. Trends in HIV/AIDS diagnoses among men who have sex with men\33 states, 2001-2006. MMWR Morb Mortal Wkly Rep 2008 57 681-686.
44. CDC. Subpopulation estimates from the HIV incidence surveillance system\United States, 2006. MMWR Morb Mortal Wkly Rep 2008 57 985-989.
45. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562-569.
46. Pallela FJ Jr, Baker RK, Moorman AC, et al; the HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr. 2006;43:27-34.
47. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908-914.
48. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic, non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899-1905.
49. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr. 2001;26:340-344.
50. George SL, Gebhardt J, Klinzman D, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr. 2002;31:154-162.
51. Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol. 2000;38:575-577.
52. Carithers RL, Marquardt A, Gretch DR. Diagnostic testing for hepatitis C. Hepatitis C: State of the Art at the Millennium (part 2). Semin Liver Dis. 2000;20:159-171.